Alamar Biosciences Raises Full-Year Outlook Following 68% Q3 Revenue Growth
Alamar Biosciences (ALMR) reported significant momentum in its third quarter, highlighted by a 68% year-over-year increase in total revenue. This growth was primarily driven by a 79% surge in consumables sales, which contributed to improved profit margins and prompted management to raise the company's full-year financial outlook. Looking ahead, the company has provided revenue guidance of $121 million to $123 million for 2026. Additionally, Alamar is advancing its regulatory pipeline, with plans to submit FDA applications for its ARGO HT and DX products by the end of next year.
Tickers: $ALMR
Topics: guidance upgrade margin expansion quarterly earnings revenue growth